<DOC>
	<DOCNO>NCT01920399</DOCNO>
	<brief_summary>Investigate safety tolerability , well PK profile ceftazidime-avibactam ( CAZ -AVI ) administer single repeat intravenous ( IV ) infusion healthy Chinese subjects.This study data use support CAZ-AVI NDA China .</brief_summary>
	<brief_title>A Phase I Study Assess Safety , Tolerability PK Ceftazidime-Avibactam Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<criteria>Key Provision sign date , write informed consent prior studyspecific procedure . Healthy male female ( nonchild bear potential ) Chinese subject , suitable vein cannulation repeat venipuncture BMI 19 24 kg/m2 inclusive weigh least 50 kg 100 kg . Key Any clinical condition require regular use medication . Consumption alcohol , drug , tobacco ( cigarette ) . Sensitive food , serious reaction carbapenem , cephalosporin , Î²lactam antibiotic . Severe medical psychiatric condition laboratory abnormality . Blood donation . 12 lead ECG abnormal .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CAZ-AVI China phase I PK study</keyword>
</DOC>